芪參二蓮湯聯(lián)合恩替卡韋治療乙型肝炎肝纖維化臨床研究
發(fā)布時(shí)間：2019-04-03 07:04
【摘要】：目的觀察芪參二蓮湯聯(lián)合恩替卡韋片治療乙型肝炎肝纖維化的臨床療效。方法將74例乙型肝炎肝纖維化患者隨機(jī)分為治療組38例和對(duì)照組36例。對(duì)照組給予恩替卡韋片,治療組在對(duì)照組治療基礎(chǔ)上加用芪參二蓮湯。48周為1個(gè)療程,治療結(jié)束后繼續(xù)給予恩替卡韋片,并隨訪24周。比較2組患者治療前后肝功能、HBV-DNA、血清轉(zhuǎn)化生長(zhǎng)因子-β1(TGF-β1)、骨形態(tài)發(fā)生蛋白7(BMP-7)、肝纖維化指標(biāo)及臨床癥狀的變化。結(jié)果治療組剔除3例、失訪3例,對(duì)照組失訪6例。治療組治療12、24、36、48周及隨訪24周時(shí)肝功能指標(biāo)、HBV-DNA均較治療前明顯下降(P0.01),且均明顯優(yōu)于對(duì)照組(P0.01)。與治療前比較,2組治療后TGF-β1均下降(P0.05),BMP-7均升高(P0.01),TGF-β1/BMP-7比值均下降(P0.01),組間比較差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療組治療后及隨訪時(shí)透明質(zhì)酸、層黏連蛋白、Ⅲ型前膠原、Ⅳ型膠原、肝臟彈性成像較治療前明顯下降(P0.01),與對(duì)照組比較差異有統(tǒng)計(jì)學(xué)意義(P0.01)。治療組治療后及隨訪時(shí)乏力、肝區(qū)不適、惡心厭油及納差均明顯好轉(zhuǎn),與對(duì)照組比較差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論芪參二蓮湯聯(lián)合恩替卡韋片具有良好的保肝降酶、抗病毒及逆轉(zhuǎn)肝纖維化的作用。
[Abstract]:Objective to observe the clinical effect of Qishen Erlian decoction combined with enecavir tablet in treatment of hepatitis B liver fibrosis. Methods 74 patients with hepatitis B liver fibrosis were randomly divided into treatment group (38 cases) and control group (36 cases). The treatment group was treated with Qishen Erlian decoction on the basis of the control group. 48 weeks was a course of treatment. After the treatment, the patients were given ntekavel tablets and followed up for 24 weeks. The changes of liver function, HBV-DNA, serum transforming growth factor-尾 1 (TGF- 尾 1), bone morphogenetic protein 7 (BMP-7), hepatic fibrosis indexes and clinical symptoms were compared between the two groups before and after treatment. Results in the treatment group, 3 cases were excluded, 3 cases lost follow-up, and 6 cases in the control group. After 12, 24, 36, 48 weeks and 24 weeks of follow-up, the liver function indexes and HBV-DNA in the treatment group were significantly lower than those before treatment (P0.01), and were significantly better than those in the control group (P0.01). Compared with pre-treatment, TGF- 尾 1 decreased (P0.05), BMP-7 increased (P0.01), TGF- 尾 1 / BMP-7 ratio decreased (P0.01), the difference between the two groups was statistically significant (P0.05). Hyaluronic acid, laminin, type 鈪，
本文編號(hào)：2453007
[Abstract]:Objective to observe the clinical effect of Qishen Erlian decoction combined with enecavir tablet in treatment of hepatitis B liver fibrosis. Methods 74 patients with hepatitis B liver fibrosis were randomly divided into treatment group (38 cases) and control group (36 cases). The treatment group was treated with Qishen Erlian decoction on the basis of the control group. 48 weeks was a course of treatment. After the treatment, the patients were given ntekavel tablets and followed up for 24 weeks. The changes of liver function, HBV-DNA, serum transforming growth factor-尾 1 (TGF- 尾 1), bone morphogenetic protein 7 (BMP-7), hepatic fibrosis indexes and clinical symptoms were compared between the two groups before and after treatment. Results in the treatment group, 3 cases were excluded, 3 cases lost follow-up, and 6 cases in the control group. After 12, 24, 36, 48 weeks and 24 weeks of follow-up, the liver function indexes and HBV-DNA in the treatment group were significantly lower than those before treatment (P0.01), and were significantly better than those in the control group (P0.01). Compared with pre-treatment, TGF- 尾 1 decreased (P0.05), BMP-7 increased (P0.01), TGF- 尾 1 / BMP-7 ratio decreased (P0.01), the difference between the two groups was statistically significant (P0.05). Hyaluronic acid, laminin, type 鈪，
本文編號(hào)：2453007
本文鏈接：http://sikaile.net/yixuelunwen/chuanranbingxuelunwen/2453007.html
最近更新
教材專著
